🇺🇸 FDA
Pipeline program

QL2107, PEMBROLIZUMAB

QL2107-102

Phase 3 small_molecule active

Quick answer

QL2107, PEMBROLIZUMAB for Non-small cell lung cancer is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Non-small cell lung cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials